Advertisement
Screener

Tenaya Therapeutics, Inc. (TNYA) Material Contracts

Tenaya Therapeutics, Inc. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2026-08-05: Form 10-Q; Exhibit 10.4; Description First Amendment to Loan and Security Agreement by and between Silicon Valley Bank, a division of First-Citizens Bank & Trust Company and Tenaya Therapeutics, Inc..
  • 2026-08-05: Form 10-Q; Exhibit 10.3; Description Outside Director Compensation Policy.
  • 2026-06-29: Form 8-K; Exhibit 10.1; Description Offer Letter by and between the Company and Eric Hyllengren, dated as of June 18, 2026.
  • 2026-05-29: Form 8-K; Exhibit 10.1; Description Amended and Restated 2021 Equity Incentive Plan.
FiledFormExhibitDescription
2026-08-0510-Q10.4First Amendment to Loan and Security Agreement by and between Silicon Valley Bank, a division of First-Citizens Bank & Trust Company and Tenaya Therapeutics, Inc.
2026-08-0510-Q10.3Outside Director Compensation Policy
2026-06-298-K10.1Offer Letter by and between the Company and Eric Hyllengren, dated as of June 18, 2026
2026-05-298-K10.1Amended and Restated 2021 Equity Incentive Plan
2026-05-0610-Q10.2Collaboration Agreement by and between Alnylam Pharmaceuticals, Inc. and Tenaya Therapeutics, Inc.
2026-03-1110-K10.11Outside Director Compensation Policy.
2026-01-308-K10.1Tenaya Therapeutics, Inc. 2024 Inducement Equity Incentive Plan, as amended, and related forms of stock option and restricted stock unit agreements.
2025-03-1010-K10.10Employment Letter between the Registrant and Tomohiro Higa, M.B.A.
2024-11-0610-Q10.1Loan and Security Agreement by and between Silicon Valley Bank, a division of First-Citizens Bank & Trust Company and Tenaya Therapeutics, Inc.
2024-09-168-K10.1Tenaya Therapeutics, Inc. 2024 Inducement Equity Incentive Plan and related forms of stock option and restricted stock unit agreements
2024-08-0810-Q10.1First Amendment to Lease between HCP Oyster Point III LLC and the Registrant dated as of September 6, 2016.
2024-03-1810-K10.10Outside Director Compensation Policy.
2023-11-0810-Q10.1Outside Director Compensation Policy
2023-06-128-K10.1Executive Change in Control and Severance Plan, as amended
2023-05-1010-Q10.1Outside Director Compensation Policy
2023-03-0810-K10.10Outside Director Compensation Policy.
2022-03-2310-K10.22021 Equity Incentive Plan and forms of agreements thereunder.

Similar stocks

Stock NameCountryMarket CapPE Ratio
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99